Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis

Primary outcomes

1. Age

   Time frame: Baseline

   Age information was reported.

2. Gender

   Time frame: Baseline

   Gender information was reported.

3. Number of patients with Reimbursement scheme

   Time frame: Baseline

   Reimbursement scheme information was reported.

4. Weight

   Time frame: During 3 months pre-baseline

   Weight information was reported.

5. Height

   Time frame: During 3 months pre-baseline

   Height information was reported.

6. BMI

   Time frame: During 3 months pre-baseline

   BMI information was reported.

7. Co-morbidities

   Time frame: During 12 months pre-baseline

   • Crohn's Disease
   • Diabetes Mellitus
   • Dyslipidemia
   • Hypertension
   • Inflammatory Bowel Disease
   • Latent Tuberculosis
   • Psoriatic Arthritis (PsA)

8. Psoriasis Area and Sensitivity Index (PASI) score

   Time frame: During 4 weeks pre-baseline

   Psoriasis Area and Severity Index (PASI) is the most widely used tool for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease).

9. Percentage of Body Surface Area (BSA) involvement

   Time frame: During 4 weeks pre-baseline

   Percentage of Body Surface Area (BSA) involvement was reported.

10. Disease Life Quality Index (DLQI) score

    Time frame: During 4 weeks pre-baseline

    The Dermatology Life Quality Index (DLQI) is a simple, self-administered and user-friendly validated questionnaire. The DLQI is designed to measure the health-related quality of life of adult patients suffering from a skin disease. The DLQI is a validated, 10-question, self-reported questionnaire to evaluate the patient's perception of the impact of psoriasis on quality of life. The DLQI was rated on a 4-point scale (0 = not at all to 3 = very much). The highest possible total score for the DLQI is 30 and higher scores indicate more severe impact on quality of life.

11. Date of first symptom of psoriasis (PSO) / year

    Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)

    To describe the PSO treatment history

12. Date of psoriasis diagnosis / year

    Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)

    To describe the PSO treatment history

13. Duration of psoriasis diagnosis

    Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)

    To describe the PSO treatment history

14. Date of first systemic treatment/ year

    Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)

    To describe the PSO treatment history

15. Date of first biologic agent/year

    Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)

    To describe the PSO treatment history

16. Duration of topical therapy

    Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)

    To describe the PSO treatment history

17. History of topical therapy

    Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)

    To describe the PSO treatment history

18. Duration of systemic therapy

    Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)

    To describe the PSO treatment history

19. History of systemic therapy

    Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)

    To describe the PSO treatment history

20. Duration of biologic therapy

    Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)

    To describe the PSO treatment history

21. History of biologic therapy

    Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)

    To describe the PSO treatment history

22. Date of PsA diagnosis/year

    Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)

    To describe the PSO treatment history

23. Duration of PsA diagnosis

    Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)

    To describe the PSO treatment history

24. Number of patients with baseline PSO treatment

    Time frame: During 12 months pre-baseline

    Topical Therapies

    • Topical corticosteroid
    • Coal tar
    • Salicylic acid
    • Vitamin D analogues
    • Anthralin
    • Calcineurin inhibitors
    • Others Oral systemic therapies
    • Methotrexate
    • Acitretin
    • Retinoid
    • Cyclosporine
    • Azathioprine
    • Hydroxyurea
    • Leflunomide
    • Sulfasalazine
    • Others Biologic therapy
    • Infliximab
    • Etanercept
    • Ustekinumab
    • Brodalumab
    • Guselkumab
    • Ixekizumab
    • Others

25. Duration since the discontinuation of the latest biological agents

    Time frame: Baseline

    Secukinumab therapy

26. Medication use concomitant to index secukinumab prescription

    Time frame: Baseline

    Secukinumab therapy

27. Treatment pattern with secukinumab

    Time frame: Baseline

    Secukinumab therapy

28. Treatment duration since the first dosing till the most recent dosing

    Time frame: Baseline

    Secukinumab therapy